Skip to main content

Table 3 Clinical efficacy of NGX-4010 in patients with PHN duration ≥ 6 months (180 days)

From: Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia

NPRS Scores

NGX-4010

(n = 86)

Control

(n = 43)

P-value

Baseline, LS mean (SE)

5.4 (0.17)

5.2 (0.24)

 

   95% CI

5.05, 5.72

4.77, 5.72

 

Change, mean (SE)

   

   Baseline to weeks 2 to 8

-1.8 (0.20)

-1.4 (0.29)

0.072

   95% CI

-2.18, -1.38

-1.92, -0.79

 

   Baseline to weeks 2 to 12

-1.8 (0.20)

-1.3 (0.28)

0.160

   95% CI

-2.23, -1.44

-1.90, -0.78

 

Percent Change, mean (SE)

   

   Baseline to weeks 2 to 8

-37.6 (3.66)

-23.4 (5.21)

0.0291

   95% CI

-44.85, -30.35

-33.74, -13.10

 

   Baseline to weeks 2 to 12

-37.5 (3.76)

-25.5 (5.35)

0.069

   95% CI

-44.98, -30.10

-36.06, -14.88

 

Patients with ≥ 30% reduction, %

   

   Baseline to weeks 2 to 8

49

40

0.090

   Baseline to weeks 2 to 12

50

44

0.277

Patients with ≥ 50% reduction, %

   

   Baseline to weeks 2 to 8

35

30

0.270

   Baseline to weeks 2 to 12

40

28

0.065

PGIC

   

   Improved (very much, much)

   

   Week 4, n

84

40

 

N (%)

31 (37)

14 (35)

1.0000

   Week 8, n

78

35

 

N (%)

34 (44)

10 (29)

0.1487

   Week 12, n

81

41

 

N (%)

32 (40)

8 (20)

0.0403